Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort

Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort

Abstract Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed. We treated a multi-ethnic cohort of 31 diffuse large B-cell lymphoma patients with axicabtagene ci...

Full description

Bibliographic Details
Main Authors: Emma Rabinovich, Kith Pradhan, R. Alejandro Sica, Lizamarie Bachier-Rodriguez, Ioannis Mantzaris, Noah Kornblum, Aditi Shastri, Kira Gritsman, Mendel Goldfinger, Amit Verma, Ira Braunschweig
Format: Article
Language:English
Published: BMC 2021-12-01
Series:Experimental Hematology & Oncology
Subjects:
CAR T-cell therapy
DLBCL
LDH
Online Access:https://doi.org/10.1186/s40164-021-00248-9

Internet

https://doi.org/10.1186/s40164-021-00248-9

Similar Items